Agents that activate PKG1 through augmentation of cGMP, including nitrates (3), sacubitril/valsartan (4), and vericiguat (5), now represent a rapidly emerging class of drugs that has improved outcomes in heart failure (HF) with reduced ejection fraction. This evidence concerns the gene PRKG1 and heart failure.